Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference

Published

on

<!– Name:DistributionId Value:8835163 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:4573 –> <!– Name:CustomerId Value:1245088 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:f51d1670-faa7-4215-8a65-cd34df5a2907 –>

GUILFORD, Conn., May 09, 2023 (GLOBE NEWSWIRE) — AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today Dr Antje Prasse of Fraunhofer ITEM and Hannover Medical School, Germany, will present a scientific poster, sponsored and co-authored by the Company, at the upcoming 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023 in Washington, DC.

The abstract information is provided below:

Thematic Poster Session C34: Sarcoidosis, Fibrosis, and Proteinosis

Date: May 23, 2023

Presentation Time: 11:30a-1:15p

Location: Area F, Hall C (Lower Level) Walter E. Washington Convention Center

Abstract P649: High mTOR Activity in Bronchoalveolar Lavage Cells from Patients with Sarcoidosis

Multiple studies in humans and in animals have implicated mTOR signaling in the pathogenesis of sarcoidosis. Knock out of the TSC2 gene (an upstream regulator of mTOR) in mice leads to the formation of granulomas very similar to those seen in human sarcoidosis1. These studies suggest that mTOR activation and subsequent activation of inflammatory immune responses involving innate immune cells, such as monocytes, macrophages and dendritic cells, is a key contributor to sarcoidosis. Treatment in a sarcoidosis animal model with an mTOR inhibitor has been shown to resolve the granuloma formation.

In humans, there are case reports describing similar resolution of sarcoidosis with oral rapamycin2,3,4. Furthermore, studies of patients with progressive pulmonary sarcoidosis demonstrated alterations in genes affecting the mTOR pathway5 and analysis of patient tissues demonstrated activated mTOR signaling6.

About LAM-001

LAM-001 is a proprietary, investigational, inhaled formulation of sirolimus, also known as rapamycin. LAM-001 inhibits the mTOR pathway which has been implicated in multiple pulmonary indications. By delivering the drug directly to the lung, LAM-001 has the potential to deliver the benefits of sirolimus while reducing systemic exposure and the toxicities associated with oral sirolimus administration. AI Therapeutics is developing LAM-001 for the treatment of pulmonary sarcoidosis, pulmonary arterial hypertension (PAH) and bronchiolitis obliterans syndrome (BOS) post lung transplant.

About AI Therapeutics

AI Therapeutics was founded by Dr. Jonathan Rothberg, serial entrepreneur and recipient of the National Medal of Technology and Innovation for inventing high speed “Next-Gen” DNA sequencing, with the goal of utilizing artificial intelligence to accelerate the clinical development of drugs for rare diseases. The company is building out an expansive rare disease pipeline with the help of its Guardian AngelTM Platform, a suite of artificial intelligence tools that use deep learning to understand complex disease biology and the action of potential new therapeutics. To learn more, visit: AI-Therapeutics.com.

_______________________________

1 Linke M, Pham HT, Katholnig K, Schnöller T,Miller A, Demel F, Schütz B,Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ,Weichhart T. Chronic signaling via the metabolic checkpoint kinase mTORC1induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017 Mar;18(3):293-302. doi:10.1038/ni.3655. Epub 2017 Jan 16. PMID: 28092373.

2 Manzia TM, Bellini MI, Corona L, Toti L, Fratoni S, Cillis A, Orlando G, Tisone G. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011 Aug;24(8):e69-70. doi: 10.1111/j.1432-2277.2011.01256.x. Epub 2011Apr 19. PMID: 21504488

3 Kelleher,K. J., Russell, J., Killeen, O. G., & Leahy, T. R. (2020).Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Reports, 13(8), e235372. doi:/10.1136/bcr-2020-235372

4 Gupta N, Bleesing JH, McCormack FX. Successful Response to Treatment with Sirolimus in Pulmonary Sarcoidosis. Am J Respir Crit Care Med.2020 Nov 1;202(9):e119-e120. doi:10.1164/rccm.202004-0914IM. PMID: 32730705.

5 Calender A, Lim CX, Weichhart T, Buisson A, Besnard V, Rollat-Farnier PA, Bardel C, Roy P, Cottin V, Devouassoux G, Finat A, Pinson S, Lebecque S, Nunes H, Israel-Biet D, Bentaher A, Valeyre D, Pacheco Y; in the frame of GSF (Group Sarcoidosis France). Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signaling and autophagy in familial sarcoidosis. Eur Respir J. 2019 Aug 1;54(2):1900430. doi:10.1183/13993003.00430-2019. PMID: 31023854.

6 Linke M, Pham HT, Katholnig K, Schnöller T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ, Weichhart T. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017 Mar;18(3):293-302. doi:10.1038/ni.3655. Epub 2017 Jan 16. PMID: 28092373.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

New first of its kind UK legal-tech recruitment platform aims to put an end to overseas worker scams

Published

on

new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams

Unique UK-based legal technology platform, Immpact, helps unite the global talent market to fulfil UK skills shortages across healthcare, construction, engineering, life sciences and hospitality Immpact directly connects employers, recruiters and regulated legal experts with pre-qualified global talent – and aims to help eradicate profiteering job scammersREADING, England, May 28, 2024 /PRNewswire/ — A unique new legal-tech recruitment platform has launched in the UK to help put an end to overseas worker scams and directly connect UK employers and recruiters with pre-qualified overseas global talent. Immpact will help fulfil acute skills shortages across sectors including healthcare, construction, engineering, life sciences and hospitality, while ensuring full legal Home Office compliance.

The launch of Immpact follows over two years of advanced legal-tech development. Using the immigration law expertise of Founder and Managing Director, Jonathan Beech, and his team of specialists, the platform will help unite a previously disconnected global talent market with under-resourced UK employers and transform global workplace migration. Immpact has also been developed through discussions with hundreds of employers, industry bodies and overseas talent.
With job scams – from fake jobs to illegal fees for sponsor licences – ongoing, particularly in the social and healthcare sector, Immpact will ensure only pre-qualified talent, employers and recruitment firms are placed on its platform following stringent multi-layer checks. This will ensure that all jobs and talent are qualified and genuine along with thoroughly regulated employers and recruiters, to provide a global marketplace for talent.
Jonathan Beech, Founder and Managing Director of Immpact, said: “Through my existing business running Migrate UK, I’m acutely aware of the issues that UK employers and recruiters are having in trying to fulfil talent shortages across sectors such as care, healthcare and life sciences. I also regularly hear terrible stories of genuine overseas job hunters being ripped off in their home countries or the UK by job scammers, often running to thousands of pounds.
“I knew there had to be a better way to match pre-qualified overseas talent with genuine work opportunities and responsible UK employers – effectively a ‘talent’ match-making site which is designed to eradicate scammers to provide a global, trusted marketplace for talent.”
Following the latest government immigration rule changes, overseas recruitment costs are continuing to rise for businesses struggling with talent shortages. From 4 April 2024, the minimum salary for entering the new skilled visa worker route for the first time increased by 48%, from £26,200 to £38,700 a year. There are different rates for those already holding a skilled worker certificate of sponsorship prior to this date and discounts are available for key shortage roles on the Immigration Salary List (ISL).
Immpact will benefit employers and recruiters by saving them time and money. Working with recruitment experts to analyse existing overseas recruitment workflows, Immpact has calculated that it will save 50% of the time involved in managing overseas recruitment, helping to cut down the time-consuming filtering of applications traditionally needed.
For employers traditionally looking to recruit overseas applicants, previous data from industry recruitment software specialists show that 30% of overseas applications are rejected as they do not have the right to work, while 64% are rejected due to CVs being unclear or requirements not being met. This leaves just 6% of applications remaining, which results in about 2% then being interviewed. Immpact will automatically present only suitable pre-qualified applications to employers or recruiters, eradicating wasted time on unsuitable or unqualified applicants.
Beech continues: “Following thousands of hours of development and utilising the latest advanced technology which can adapt to evolving Home Office requirements and procedures, we’re proud to launch Immpact. Our unique new platform takes care of the entire process – from pre-qualifying processes, searching and shortlisting, down to arranging interviews, successful appointments, onboarding, the provision of regular content and guidance, and access to regulated immigration legal professionals.
“Our new technology will transform global migration for both UK organisations and businesses struggling to recruit and global talent looking to work in the UK. Immpact has been thoroughly tested at every stage and is both user-friendly and, crucially, compliant, so qualified overseas applicants and UK employers and recruiters can be confident that only genuine UK jobs and overseas applicants match and proceed. Quite simply, we want Immpact to simplify the whole migration process by putting the right talent in the right place at the right time, and for UK employers to fulfil critical talent shortages which will help them not only survive, but thrive.”
The platform has a free trial or low-cost subscriber options for search-matching and more for employers and recruiters. For talent, the platform has zero costs for creating a profile, using the pre-qualifying tools or searching for opportunities. For further information visit www.immpact.ai.
Photo – https://mma.prnewswire.com/media/2421643/Founder_and_Managing_Director_Immpact.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/new-first-of-its-kind-uk-legal-tech-recruitment-platform-aims-to-put-an-end-to-overseas-worker-scams-302155226.html

Continue Reading

Artificial Intelligence

Bluecrux supports Sanofi in harnessing AI to transform supply chains for tomorrow

Published

on

bluecrux-supports-sanofi-in-harnessing-ai-to-transform-supply-chains-for-tomorrow

BARCELONA, Spain, May 28, 2024 /PRNewswire/ — Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design and improving the manufacturing and supply of medicines and vaccines to get them to patients in need faster. Bluecrux’s digital supply chain twin technology, Axon, plays a critical role in Sanofi’s digital supply chain transformation.

Delivering miracles of science to patients
The company is paving the way as a leader in innovation among pharma companies with its broad AI implementation, enhancing operational capabilities across various domains of the business. Sanofi’s ambition is particularly pronounced in its supply chain strategy, in which AI is pivotal in “delivering miracles of science to patients.”  With greater efficiency, the company can redirect savings toward R&D and medicine development.
Bluecrux’s Axon plays a critical role in Sanofi’s digital supply chain transformation. Axon is a digital twin that integrates and harmonizes all Sanofi’s data systems into ONE single digital value chain model. This allows for a comprehensive understanding of Sanofi’s supply chain operations from start to finish. “The end-to-end visibility of our supply chain value stream has already helped us identifying large opportunities to improve inventory and process cycle times that will ultimately get our products to patients faster”, says Leif Skibsted Jakobsen, Head of Digital Supply Chain Sanofi. “We have put in place a structured process for implementing these opportunities and with Axon we are also able to validate the results.”
“Axon is an important puzzle piece in supporting Sanofi’s aims to create an E2E-connected, data driven and digitally accelerated supply chain”, adds Valerie Vandenbroucke, VP for Axon Technology Bluecrux. “Although the use of the platform is already transformational, the journey has just begun, with many more breakthroughs on the horizon.”
Sanofi and Bluecrux at Gartner Barcelona
At the upcoming Gartner Supply Chain Symposium EMEA conference in Barcelona (June 10-12), Bluecrux will join Sanofi in a special session that will delve into the transformative power of artificial intelligence in the realm of supply chain management. Valérie Vandenbroucke, VP of Bluecrux’s Axon Technology, and Sanofi’s Leif Skibsted Jakobsen will be co-presenting.
During the session, attendees will gain insights into how Sanofi has harnessed AI to meet and exceed its business objectives. It will explore how Sanofi translated its vision into a practical roadmap and how AI can catalyze a true transformation in supply chain management, including helping the company become an E2E-connected, data-driven and digitally accelerated supply chain.
About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Bluecrux
Founded in 2011, Bluecrux is a leading value chain technology and consulting company, assisting global companies to navigate and improve their supply chains. The company’s global reach and innovative technologies, Binocs and Axon, reflect its goal to combine expertise with technology, turning challenges into opportunities. 

View original content:https://www.prnewswire.co.uk/news-releases/bluecrux-supports-sanofi-in-harnessing-ai-to-transform-supply-chains-for-tomorrow-302156155.html

Continue Reading

Artificial Intelligence

Slovenian Tourist Board Unveils Innovative Projects to Enhance Tourism and Sports Visibility: Audio Stories, AI-Powered Virtual Assistant, and “Slovenia – Sports Destination” Website

Published

on

slovenian-tourist-board-unveils-innovative-projects-to-enhance-tourism-and-sports-visibility:-audio-stories,-ai-powered-virtual-assistant,-and-“slovenia-–-sports-destination”-website

LJUBLJANA, Slovenia, May 28, 2024 /PRNewswire/ — Slovenia is a land of countless natural beauties, cultural treasures, top health and wellness resorts and superb gastronomy, which the Slovenian Tourist Board aims to showcase to visitors in an innovative and attractive way. To achieve this, the Board continually analyzes current marketing trends and develops projects designed to excite tourists, spark their curiosity and inspire them to explore further.

By staying at the forefront of marketing strategies, the Slovenian Tourist Board ensures that the country’s unique attractions are presented in the most engaging and appealing manner possible. The most recent projects to boost Slovenia’s visibility include three new projects: Sounds Like Slovenia, a series of audio stories, an AI-powered virtual assistant named Alma on slovenia.info and the “Slovenia – Sports Destination” website.
More
Meet Alma, an AI-powered virtual assistant
Alma, named after the adventurous traveller and writer Alma M. Karlin, operates using advanced AI technology, filtering content to suit user interests. She sources reliable information from the slovenia.info database and over 50 verified websites of Slovenian tourist destinations and providers. As one of the first AI assistants in Slovenian tourism, and among the few AI assistants integrated in national tourism organizations’ websites in Europe, Alma positions slovenia.info as a reliable source of information and inspiration for international visitors.
More
Slovenia – Sports Destination Website
The Slovenia–Sports Destination website serves as a comprehensive resource for organizing sports activities and events, conferences, rehabilitation and inspiration, available in both Slovenian and English. Sports agencies, clubs, and event organizers can use the portal to connect directly with relevant partners in Slovenia. The website also provides direct contacts for specialized sports agencies and federations, assisting with the organization of preparatory matches and other logistical needs. Information on sports accommodations is also available.
More
Sounds Like Slovenia 
Thematic playlists on Spotify and sound stories on slovenia.info provide an immersive audio experience of Slovenia’s landscapes and cultural offerings. Themes are categorized into five categories: the Sounds of Nature, Thrilling Outdoor Adventures, Cities and Culture, Health and Well-Being, and Gastronomy. Crafted for the global digital campaign, the audio list aims to captivate travelers worldwide.
More
Together, these projects demonstrate Slovenia’s dedication to innovation and sustainability in tourism, offering visitors unforgettable experiences in this vibrant European destination with a green heart.
Photo: https://mma.prnewswire.com/media/2422785/Sounds_like_slovenia.jpg

View original content:https://www.prnewswire.co.uk/news-releases/slovenian-tourist-board-unveils-innovative-projects-to-enhance-tourism-and-sports-visibility-audio-stories-ai-powered-virtual-assistant-and-slovenia—sports-destination-website-302156165.html

Continue Reading

Trending